Increase cancer treatment success rates with LBL’s revolutionary liquid biopsy for cancer screening and diagnosis.
"Liquid biopsies," one of the hottest trends in oncology, couldyield a less painful and risky...Pollack, Andrew
It was the first PCR-based ctDNA test designed to detect epidermal growth factor receptor (EGFR) gene mutations from the blood of patients with non–small cell lung cancer (NSCLC). PCR-based detection of ctDNA in liquid biopsy is considered an attractive approach to molecular cancer screening ...
Testing the blood for ctDNA and a tissue biopsy can provide a more complete picture of a cancer’s genetics. This is because pooling of all fragments in the circulatory system may result in the identification of ctDNA mutations that arise outside of and are not present in the primary tumor...
These blood tests could detect cancer before any symptoms surface.Liquid Biopsy Detecting cancer using a simple blood test — a "liquid biopsy" — is a relatively new development. The appeal of such a procedure is understandable, though, as current cancer screening techniques can be expensive, ca...
point is early detection via cell-free DNA (cfDNA) circulating in the bloodstream – the so-called “liquid biopsy.” However, using this method to detect cancer at its early stages has been challenging due to the genetic diversity of cancer and low tumor concentrations in DNA blood fra...
标题(英文):Clinical validation of a next-generation sequencing-based multi-cancer early detection “liquid biopsy” blood test in over 1,000 dogs using an independent testing set: The CANcer Detection in Dogs (CANDiD) study 标题(中文):利用独立测试集,在 1,000 多只狗身上对基于下一代测序的多癌...
Molecular diagnostics companyPetDxhas published the results of a clinical validation study for its proprietary product, OncoK9, a multi-cancer early detection (MCED) test for dogs that uses next-generation sequencing (NGS) of blood-derived DNA. ...
Karius, based in Redwood City, California, USA, sees this as three million opportunities to improve patient outcomes and change lives. The company has developed the Karius Test, a cell-free DNA (cfDNA)-based blood test much like the liquid biopsies that detect cancer DNA from a single blood...
The development of detection technology has provided basis for liquid biopsy. Nowadays, liquid biopsy has received enormous attention as it can serve as a minimally invasive approach for early detection of cancer [12]. Liquid biopsies mainly include cfDNA, CTCs, and exosomes. Also, sputum, bronchoa...